Pub Date : 2017-01-01DOI: 10.5455/BCP.20161218085312
V. Gormez, A. Kilincaslan, A. Orengul, Chad Ebesutani, İlyas Kaya, V. Çeri, S. Nasıroğlu, Mekiya Filiz, B. Chorpita
{"title":"Psychometric properties of the Turkish translation of the Revised Child Anxiety and Depression Scale- Child Version (RCADS-CV) in a clinical sample","authors":"V. Gormez, A. Kilincaslan, A. Orengul, Chad Ebesutani, İlyas Kaya, V. Çeri, S. Nasıroğlu, Mekiya Filiz, B. Chorpita","doi":"10.5455/BCP.20161218085312","DOIUrl":"https://doi.org/10.5455/BCP.20161218085312","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"43 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88238902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/BCP.20110403020951
Deepak Narang, Sara E. Tomlinson, A. Holt, D. Mousseau, G. Baker
The arylalkylamines, s-phenylethylamine, m- and p-tyramine, tryptamine, m- and p-octopamine, phenylethanolamine and synephrine, have been termed trace amines because of their low absolute concentrations in the central nervous system relative to the classical neurotransmitter amines, noradrenaline, dopamine and 5-hydroxytryptamine (5-HT, serotonin). Despite being present at low concentrations, these amines have been implicated in the etiology and pharmacotherapy of several psychiatric and neurological disorders. Studies on trace amines þourished in the 1970s and 1980s, following the development of sensitive assays for these amines, and were accompanied by comprehensive electrophysiological studies and some receptor binding studies. There has been a resurgence of interest in these amines in the past decade with the discovery and cloning of a unique family of G-protein-coupled receptors, some of which are selectively activated by trace amines; these receptors have been termed trace amine, associated receptors (TAARs). The relevance of these receptors to the actions of the trace amines and to the actions of several other neurochemicals and psychotropic drugs is discussed.
{"title":"Trace Amines and Their Relevance to Psychiatry and Neurology: A Brief Overview","authors":"Deepak Narang, Sara E. Tomlinson, A. Holt, D. Mousseau, G. Baker","doi":"10.5455/BCP.20110403020951","DOIUrl":"https://doi.org/10.5455/BCP.20110403020951","url":null,"abstract":"The arylalkylamines, s-phenylethylamine, m- and p-tyramine, tryptamine, m- and p-octopamine, phenylethanolamine and synephrine, have been termed trace amines because of their low absolute concentrations in the central nervous system relative to the classical neurotransmitter amines, noradrenaline, dopamine and 5-hydroxytryptamine (5-HT, serotonin). Despite being present at low concentrations, these amines have been implicated in the etiology and pharmacotherapy of several psychiatric and neurological disorders. Studies on trace amines þourished in the 1970s and 1980s, following the development of sensitive assays for these amines, and were accompanied by comprehensive electrophysiological studies and some receptor binding studies. There has been a resurgence of interest in these amines in the past decade with the discovery and cloning of a unique family of G-protein-coupled receptors, some of which are selectively activated by trace amines; these receptors have been termed trace amine, associated receptors (TAARs). The relevance of these receptors to the actions of the trace amines and to the actions of several other neurochemicals and psychotropic drugs is discussed.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"80 1","pages":"73-79"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85958585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/bcp.20160301092703
Kültegin Ögel, Ceren Koç, Serap Görücü
ABSTRACTObjective: The objective of this study is to develop a risk-screening questionnaire appropriate for cultural characteristics in detection of alcohol- and drug-use level through utilization of Addiction Profile Index (API) and perform the reliability and validity work thereof.Methods: The study was carried out on the sample of two previously made separate studies. Both samples were selected from inmates in prisons. API, CAGE Scale, Alcohol Use Disorders Identification Test (AUDIT), Drug Abuse Screening Test (DAST-10), Drug Use Disorders Identification Test (DUDIT) and clinical interview form structured for DSM-IV-TR (SCID-I) were employed in the study.Results: BAPIRT-alcohol and BAPIRT-drug questionnaires evaluating alcohol and drug abuse separately and each of which consisting of six questions were developed. Cronbach's alpha coefficients were found as 0.70 and 0.88 in the internal consistency analysis made with sample 1 data of BAPIRT alcohol and drug scale respectively. BAPIRT alcohol scale cons...
{"title":"STUDY ON DEVELOPMENT, VALIDITY AND RELIABILITY OF A RISK SCREENING QUESTIONNAIRE FOR ALCOHOL AND DRUG USE","authors":"Kültegin Ögel, Ceren Koç, Serap Görücü","doi":"10.5455/bcp.20160301092703","DOIUrl":"https://doi.org/10.5455/bcp.20160301092703","url":null,"abstract":"ABSTRACTObjective: The objective of this study is to develop a risk-screening questionnaire appropriate for cultural characteristics in detection of alcohol- and drug-use level through utilization of Addiction Profile Index (API) and perform the reliability and validity work thereof.Methods: The study was carried out on the sample of two previously made separate studies. Both samples were selected from inmates in prisons. API, CAGE Scale, Alcohol Use Disorders Identification Test (AUDIT), Drug Abuse Screening Test (DAST-10), Drug Use Disorders Identification Test (DUDIT) and clinical interview form structured for DSM-IV-TR (SCID-I) were employed in the study.Results: BAPIRT-alcohol and BAPIRT-drug questionnaires evaluating alcohol and drug abuse separately and each of which consisting of six questions were developed. Cronbach's alpha coefficients were found as 0.70 and 0.88 in the internal consistency analysis made with sample 1 data of BAPIRT alcohol and drug scale respectively. BAPIRT alcohol scale cons...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"7 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74989506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/bcp.20151204115629
E. Akgul, M. Erdem, A. Balıkçı, E. Aydemir, Gazi Unlu, T. Honca, A. Bolu, M. Honca, T. Çaycı
Objective: The aims of this study were to determine whether the plasma Indolamine 2,3 dioxygenase and neopterin levels in patients with major depression differ from a healthy control group and to investigate the relationship between previous major depression episodes and plasma indolamine 2,3 dioxygenase and serum neopterin levels. Methods: Thirty eight first episode major depression patients, sixty four recurrent major depression patients and forty one healthy control participant included the study. Plasma indolamine 2,3 dioxygenase and serum neopterin levels compared in these three groups. Results: Plasma indolamine 2,3 dioxygenase and serum neopterin levels in recurrent major depression group were statistically higher than first episode major depression and healthy control group. There was a positive correlation between plasma IDO levels and number of depressive episodes in major depression group (rho=0.36, p<0.001). Conclusion: According to these findings previous major depression episodes can promote response of the immune system associated with proinflamatuar cytokine activity. This sensitizing effect of previous depressive episodes may increase the recurrence risk of depression.
{"title":"Plasma Indolamine 2,3 dioxygenase and serum neopterin levels in patients with first episode major depressive disorder and recurrent major depressive disorder","authors":"E. Akgul, M. Erdem, A. Balıkçı, E. Aydemir, Gazi Unlu, T. Honca, A. Bolu, M. Honca, T. Çaycı","doi":"10.5455/bcp.20151204115629","DOIUrl":"https://doi.org/10.5455/bcp.20151204115629","url":null,"abstract":"Objective: The aims of this study were to determine whether the plasma Indolamine 2,3 dioxygenase and neopterin levels in patients with major depression differ from a healthy control group and to investigate the relationship between previous major depression episodes and plasma indolamine 2,3 dioxygenase and serum neopterin levels. Methods: Thirty eight first episode major depression patients, sixty four recurrent major depression patients and forty one healthy control participant included the study. Plasma indolamine 2,3 dioxygenase and serum neopterin levels compared in these three groups. Results: Plasma indolamine 2,3 dioxygenase and serum neopterin levels in recurrent major depression group were statistically higher than first episode major depression and healthy control group. There was a positive correlation between plasma IDO levels and number of depressive episodes in major depression group (rho=0.36, p<0.001). Conclusion: According to these findings previous major depression episodes can promote response of the immune system associated with proinflamatuar cytokine activity. This sensitizing effect of previous depressive episodes may increase the recurrence risk of depression.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"195 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76949998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/bcp.20160224100803
B. Onal, S. Kılınç, S. Hergüner
{"title":"Urticaria and Angioedema Associated with OROS-Methylphenidate","authors":"B. Onal, S. Kılınç, S. Hergüner","doi":"10.5455/bcp.20160224100803","DOIUrl":"https://doi.org/10.5455/bcp.20160224100803","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"77 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75989642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/BCP.20160223122941
O. Salawu, A. Y. Tijani, M. Adamu, Samuel Ehiabhi Okhale
{"title":"Psychopharmacological effects of methanol stem bark extract of Crossopteryx febrifuga (Afzel ex G.Don) Benth","authors":"O. Salawu, A. Y. Tijani, M. Adamu, Samuel Ehiabhi Okhale","doi":"10.5455/BCP.20160223122941","DOIUrl":"https://doi.org/10.5455/BCP.20160223122941","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"69 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72924219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.5455/bcp.20140107040932
S. Karakoç, O. Abali
{"title":"Assessment of psychopharmacological treatment in adolescents with obsessivecompulsive disorder","authors":"S. Karakoç, O. Abali","doi":"10.5455/bcp.20140107040932","DOIUrl":"https://doi.org/10.5455/bcp.20140107040932","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"89 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88545702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20161121125642
Muge Sirvanci-Yalabik, A. Sehirli, T. Utkan, F. Aricioglu
ABSTRACTObjective: Agmatine, the decarboxylation product of arginine produced by arginine decarboxylase, is a novel neurotransmitter and exists in the mammalian brain. Agmatine has been reported to modulate cognitive functions, including learning and memory.Methods: In the present study, we evaluated the effects of agmatine on cognitive performance and oxidative damage in intracerebroventricular (i.c.v.) streptozotocin (STZ) model of Alzheimer's disease (AD). Adult male Sprague-Dawley rats were injected STZ (3mg/kg, i.c.v, bilaterally) on days 1 and 3. The learning and memory patterns were assessed by using passive avoidance, Morris water maze, and closed field activity tests. Also, malondialdehyde (MDA), glutathione (GSH) levels and myeloperoxidase (MPO) activity have been determined as the parameters of oxidative damage. The behavioral tests were performed after 14 days from the first injection of STZ. Rats with impaired learning and memory performance were treated with intraperitoneal (i.p.) agmatine (...
{"title":"Agmatine, A Metabolite of Arginine, Improves Learning and Memory in Streptozotocin-Induced Alzheimer's Disease Model in Rats","authors":"Muge Sirvanci-Yalabik, A. Sehirli, T. Utkan, F. Aricioglu","doi":"10.5455/BCP.20161121125642","DOIUrl":"https://doi.org/10.5455/BCP.20161121125642","url":null,"abstract":"ABSTRACTObjective: Agmatine, the decarboxylation product of arginine produced by arginine decarboxylase, is a novel neurotransmitter and exists in the mammalian brain. Agmatine has been reported to modulate cognitive functions, including learning and memory.Methods: In the present study, we evaluated the effects of agmatine on cognitive performance and oxidative damage in intracerebroventricular (i.c.v.) streptozotocin (STZ) model of Alzheimer's disease (AD). Adult male Sprague-Dawley rats were injected STZ (3mg/kg, i.c.v, bilaterally) on days 1 and 3. The learning and memory patterns were assessed by using passive avoidance, Morris water maze, and closed field activity tests. Also, malondialdehyde (MDA), glutathione (GSH) levels and myeloperoxidase (MPO) activity have been determined as the parameters of oxidative damage. The behavioral tests were performed after 14 days from the first injection of STZ. Rats with impaired learning and memory performance were treated with intraperitoneal (i.p.) agmatine (...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"1 1","pages":"342-354"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77182639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.1080/10177833.2016.11827156
Birmay Camn
The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg
{"title":"Restless Leg Syndrome Associated with Aripiprazole","authors":"Birmay Camn","doi":"10.1080/10177833.2016.11827156","DOIUrl":"https://doi.org/10.1080/10177833.2016.11827156","url":null,"abstract":"The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"18 1","pages":"438-439"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78456906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20151209124813
S. Solomon, Ramanathan Singaravelu
ABSTRACTHyperammonemic encephalopathy is a rare, life threatening complication of valproate therapy. We describe an adult male with manic disorder and alcohol dependence who developed encephalopathy within two weeks of therapy with valproate. Risperidone and lorazepam were the concomitant medications. His serum ammonia was found to be elevated. There was complete resolution of symptoms after valproate was stopped. The patient's clinical picture was further complicated by imaging findings of ischemic changes and infarcts in the brain. Our report highlights the importance of considering hyperammonemic encephalopathy in any patients who develops acute changes in mental state while receiving valproate.
{"title":"Valproate-Induced Hyperammonemic Encephalopathy in a patient with Ischemic Stroke","authors":"S. Solomon, Ramanathan Singaravelu","doi":"10.5455/BCP.20151209124813","DOIUrl":"https://doi.org/10.5455/BCP.20151209124813","url":null,"abstract":"ABSTRACTHyperammonemic encephalopathy is a rare, life threatening complication of valproate therapy. We describe an adult male with manic disorder and alcohol dependence who developed encephalopathy within two weeks of therapy with valproate. Risperidone and lorazepam were the concomitant medications. His serum ammonia was found to be elevated. There was complete resolution of symptoms after valproate was stopped. The patient's clinical picture was further complicated by imaging findings of ischemic changes and infarcts in the brain. Our report highlights the importance of considering hyperammonemic encephalopathy in any patients who develops acute changes in mental state while receiving valproate.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":"31 1","pages":"413-416"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87043655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：